Public BoD papers 26.5.22

EXECUTIVE SUMMARY

Introduction

The Integrated Performance, Quality & Finance report presents a summary dashboard that provides an overview of performance.

Safe • There was 1 incident reported with the classification of Major and 4 as moderate in April, details of which can be found on slide 8. All the incidents are still progressing through to full root cause analysis. No never events were reported in month. • Slide 9 provides details of shared learning from incidents following Executive Reviews. • There are 5 Trust level risks scored at 15+. Details of these can be found on slides 12 & 13. • Safer staffing numbers in some areas are lower than our standard due to an increase in the number of covid related absences amongst registered and non registered nursing staff. Despite the reduced levels in some areas all shifts have been staffed to the required acuity levels to ensure appropriate levels of safety and care for our patients. Responsive • The 62 day cancer waiting time standard has not been met in April. Our position subject to validation is 79.5% for 62 days. The standard for Upgrade patients has been met with a position subject to validation of 86.5%. Within the 62 day performance we also failed to achieve the internal 24 day standard with a performance of 82.1%. All 62 and 24 day breaches are reviewed to ensure any delays are understood and plans can be implemented to mitigate any future delays . The number of patients waiting over 104 days as at the end of the month remains high and has increased from March. The majority of these patients were referred late in the pathway. The large majority of these patients are referred to the Trust over day 100. All 31 day targets and 18 week RTT standards have been achieved in April. Performance against the CWT thresholds is constantly monitored. • Referrals in April reduced from March due to the Easter holiday period, however the figure is above the comparative April 2021 total. • Activity levels are now monitored against a 22/23 plan rather than a GM recovery trajectory set around 19/20 activity levels. In month 1 Chemotherapy deliveries are significantly above plan and Radiotherapy fractions are very slightly over plan. All other points of delivery are below plan but by small margins. Effective • There have been no cases of MRSA bacteraemia. There have been 8 cases of C-Difficile that were attributable to the trust in April with no lapses in care identified. • There were 2 cases of hospital acquired nosocomial Covid-19 infections in April. Well – Led • The trust is reporting a month 1 position of £266k deficit compared to a £220k deficit plan within the latest plan submission of an annual control total deficit of £2.6m. • The month 1 EBITDA position is a surplus of £1,867k • The cash balance is £151,638k. • Capital spend to month 1 is £3,448k (39%) below the proposed plan submitted to NHSE&I, reflecting the Paterson scheme and vat recovery benefits achieved against it.

26